65,437 trials
Cervical Ripening · Labor, Induced
Primary: Minutes From Drug Insertion to Vaginal Delivery — 1595.5; 2127; 1649.5 minutes — p=0.974
Mucositis
Primary: Bleeding on Probing — 53.8; 52.3 Percentage of bleeding sites — p=0.05
Astigmatism
Primary: Subjective Reported Vision — 0.33; -0.17 Units on a scale
Rheumatoid Arthritis
Primary: Average Change in Disease Activity Score 28 (DAS 28) From the Beginning of the Treatment — 7.11; 2.94; 3.27 Units on a Scale
Stress · Pain
Primary: Difference Between All Groups for the Surgical Pleth Index(SPI) at Defined Timepoints — 46; 67; 40 SPI and delta SPI (to baseline)
HIV Infections · Hepatic Steatosis · Insulin Resistance
Primary: Hepatic Steatosis
Hypersensitivity
Primary: Hypersensitivity to Touch (Tactile) — 42.2; 20.1 Units on a scale — p=0.05
Myopia
Primary: Overall Comfort — 3.903; 3.349 Units on a scale
Breast Cancer
Primary: Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival) — 356; 352 Participants — p=0.978
Migraine Disorders
Primary: Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose — 10; 36 Participants — p=<0.001
Candidemia
Primary: Number of Subjects With Global Response of Success at End of Treatment — 31 participants
Asthma
Primary: Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52 — 0.16; 0.12 Liters — p=0.090
Pain
Primary: Difference From Baseline (Week 0) in the Average Pain Score at Visit 3 (Week 6) — -1.6 units on scale
Cataract
Primary: The Percentage of Patients With a Score of Zero for Anterior Chamber Cells. — 91.7 Percentage of participants
HIV Infections
Primary: Number of Fresh Oral Fluid Samples With Known HIV (+) Status and HIV Reactivity — 100 samples